# Anlotinib to Malignant Brainstem Glioma

> **NCT04668508** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Malignant Brain Stem Tumor
- Glioma

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04668508
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-24
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-01-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2020-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04668508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04668508, "Anlotinib to Malignant Brainstem Glioma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04668508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*